|
|
(3 intermediate revisions by one other user not shown) |
Line 2: |
Line 2: |
| |- | | |- |
| |style="background-color: #EEE"|[[Image:owwnotebook_icon.png|128px]]<span style="font-size:22px;"> Project name</span> | | |style="background-color: #EEE"|[[Image:owwnotebook_icon.png|128px]]<span style="font-size:22px;"> Project name</span> |
| |style="background-color: #F2F2F2" align="center"|<html><img src="/images/9/94/Report.png" border="0" /></html> [[{{#sub:{{FULLPAGENAME}}|0|-11}}|Main project page]]<br />{{#if:{{#lnpreventry:{{FULLPAGENAME}}}}|<html><img src="/images/c/c3/Resultset_previous.png" border="0" /></html>[[{{#lnpreventry:{{FULLPAGENAME}}}}{{!}}Previous entry]]<html> </html>}}{{#if:{{#lnnextentry:{{FULLPAGENAME}}}}|[[{{#lnnextentry:{{FULLPAGENAME}}}}{{!}}Next entry]]<html><img src="/images/5/5c/Resultset_next.png" border="0" /></html>}} | | |style="background-color: #F2F2F2" align="center"|[[File:Report.png|frameless|link={{#sub:{{FULLPAGENAME}}|0|-11}}]][[{{#sub:{{FULLPAGENAME}}|0|-11}}|Main project page]]<br />{{#if:{{#lnpreventry:{{FULLPAGENAME}}}}|[[File:Resultset_previous.png|frameless|link={{#lnpreventry:{{FULLPAGENAME}}}}]][[{{#lnpreventry:{{FULLPAGENAME}}}}{{!}}Previous entry]] }}{{#if:{{#lnnextentry:{{FULLPAGENAME}}}}|[[{{#lnnextentry:{{FULLPAGENAME}}}}{{!}}Next entry]][[File:Resultset_next.png|frameless|link={{#lnnextentry:{{FULLPAGENAME}}}}]]}} |
| |- | | |- |
| | colspan="2"| | | | colspan="2"| |
| <!-- ##### DO NOT edit above this line unless you know what you are doing. ##### --> | | <!-- ##### DO NOT edit above this line unless you know what you are doing. ##### --> |
| ==Histogram==
| |
| * It was decided to create a histogram for each inhibitor which includes the flavonoids and the non-nucleoside, acetylsalicylic acid analogs. Each inhibitor consisted of three trials.
| |
| * From Sigma, 500 μM Kaempferol (C<sub>15</sub>H<sub>10</sub>O<sub>6</sub>, MW 286.24 g/mol) stock solution was prepared in dimethylsulfoxide (DMSO).
| |
| * A kinetic assay run of 40 μM adenosine without inhibitors was executed through the kinetics of the UVProbe system.
| |
| * After the three trials of 40 μM adenosine, aspirin trials were conducted.
| |
| * The aspirin trials did not show inhibition. A possible conclusion for the inconsistency was that the aspirin stock solution has deteriorated.
| |
| * Kaempferol trials were started.
| |
| * After examining some of the data, it was concluded to adjust the 40 μM adenosine concentration to 25 μM. In addition, cuvettes will also contain 300 μL of DMSO.
| |
| * For the following week, a new aspiring stock solution will be prepared.
| |
|
| |
|
| ==adenosine vs. aspirin==
| |
| * The histogram below displays the non-inhibitory effect of aspirin.
| |
|
| |
|
| [[Image:Bar2.png]]
| |
|
| |
|
| ==Tables==
| |
| * The data below was taken from [[User:Dhea Patel/Notebook/CHEM 572: ADA&Inhibitor Kinetics/2013/03/20|Dhea Patel]].
| |
| *To measure the mass of Kaempferol and the volume of DMSO:
| |
| [[Image:Screen_Shot_2013-03-20_at_1.45.50_PM.png]]
| |
|
| |
|
| *Table of volumes and concentrations:
| |
| [[Image:Kinetics_Histogram_table.tiff|px550]]
| |
|
| |
|
|
| |
|